Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05665738 · ClinicalTrials.gov registry record · NA

Two-fraction HDR Monotherapy for Localized Prostate Cancer

A NA study of Prostate Adenocarcinoma and Localized Prostate Carcinoma, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT05665738 is a NA study of Prostate Adenocarcinoma and Localized Prostate Carcinoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 17 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05665738, a NA study of Prostate Adenocarcinoma and Localized Prostate Carcinoma, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fractions on separate days, or at least 6 hours apart. Clinically, this regimen, if shown to be safe and effective in future studies, has the potential to reduce operative resources and logistical stresses on brachytherapy departments.

Interventions

  • RADIATION High Dose Rate Monotherapy

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2024-09-11
Est. Completion 2029-02-28
Phase NA

What the Registry Record Tells You About NCT05665738

The ClinicalTrials.gov registry entry for NCT05665738 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (92% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which High Dose Rate Monotherapy is the first listed.

NCT05665738 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05665738 about?

NCT05665738 is a clinical study titled "Two-fraction HDR Monotherapy for Localized Prostate Cancer". This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fract...

What is the current status of trial NCT05665738?

This trial is currently recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2024-09-11. Estimated completion is 2029-02-28.

What conditions does trial NCT05665738 study?

This clinical trial studies the following conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma.

What interventions are being tested in trial NCT05665738?

The interventions under investigation include: High Dose Rate Monotherapy (RADIATION).

Who is sponsoring clinical trial NCT05665738?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05665738 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.